| Pharmaceutical Information |
| Drug Name |
Tenecteplase |
| Drug ID |
BADD_D02152 |
| Description |
Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain. |
| Indications and Usage |
For treatment of myocardial infarction and lysis of intracoronary emboli |
| Marketing Status |
approved |
| ATC Code |
B01AD11 |
| DrugBank ID |
DB00031
|
| KEGG ID |
D06070
|
| MeSH ID |
D000077785
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0FX8A
|
| NDC Product Code |
50242-120 |
| UNII |
WGD229O42W
|
| Synonyms |
Tenecteplase | Metalyse | TNKase |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
191588-94-0 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
